Novo Nordisk's stock is experiencing a 4.25% rebound today, trading at €40.83, as investors re-evaluate the company's raised 2026 adjusted sales and operating profit outlook, which was announced with its Q2 earnings report on August 4.
This current positive movement follows a sharp selloff on August 5, driven by initial concerns over slightly weaker-than-expected Wegovy pill sales and a setback in the CagriSema trial, which had initially overshadowed the improved guidance.
Novo Nordisk had increased its adjusted sales and operating profit growth outlook for 2026 to 0% to -6% at constant exchange rates, an improvement from previous forecasts.